Clinical trial
Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid…
NCT00359671 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00359671 |
|---|---|
| Title | Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001) |
| Official title | Phase I Study Evaluating MK6592 in Combination With Docetaxel in Adult Patients With Relapsed or Refractory Advanced Solid Tumors |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Solid Tumors |
| Intervention type | Drug |
| Interventions | MK6592, comparator: docetaxel |
| Enrollment | 38 |
| Start date | Dec 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Aug 2, 2006 |
| Last update posted | Nov 29, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: